Abstract
BackgroundThe EULAR research agenda states that new biomarkers are needed to stratify patients and to predict therapeutic response or lack of response in rheumatoid arthritis. Currently, IgG anti-citrullinated protein antibody...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
